Uterine Corpus Carcinosarcoma
Back to Diseases List
Associated Genetic Biomarkers
NCI Definition: An aggressive malignant mixed epithelial and mesenchymal tumor that arises from the uterine corpus. It usually affects elderly postmenopausal women and presents with vaginal bleeding. It is characterized by the presence of a malignant epithelial component that is usually glandular and a sarcomatous component. 
Uterine corpus carcinosarcomas most frequently harbor alterations in TP53, PIK3CA, KRAS, FBXW7, and CCNE1 .
TP53 Mutation, TP53 c.217-c.1178 Missense, TP53 Missense, PIK3CA Mutation, and TP53 Exon 7 Mutation are the most common alterations in uterine corpus carcinosarcoma .
There are 10 clinical trials for uterine corpus carcinosarcoma, of which 9 are open and 1 is completed or closed. Of the trials that contain uterine corpus carcinosarcoma as an inclusion criterion, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 8 are phase 2 (7 open).
BIRC5, Deficient, and ERBB2 are the most frequent gene inclusion criteria for uterine corpus carcinosarcoma clinical trials .
Bevacizumab, paclitaxel, and atezolizumab are the most common interventions in uterine corpus carcinosarcoma clinical trials.
Significant Genes in Uterine Corpus Carcinosarcoma
ERBB2 is altered in 7.17% of uterine corpus carcinosarcoma patients .
ERBB2 is an inclusion eligibility criterion in 1 clinical trial for uterine corpus carcinosarcoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and uterine corpus carcinosarcoma as inclusion criteria, 1 is phase 2 (1 open) .
POLE is altered in 2.22% of uterine corpus carcinosarcoma patients .
POLE is an inclusion eligibility criterion in 1 clinical trial for uterine corpus carcinosarcoma, of which 1 is open and 0 are closed. Of the trial that contains POLE status and uterine corpus carcinosarcoma as inclusion criteria, 1 is phase 2 (1 open) .
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.